Announcements Trials
Browse Landscape

Phase

Phase 2 3

Status

Recruiting 2Completed 1

Sponsor Class

OTHER 3

Study Type

Interventional 3

Sponsor

Cancer Type

Gastrointestinal 3

Conditions

Leukemia, Myeloid, Acute 150Leukemia 67Precursor Cell Lymphoblastic Leukemia-Lymphoma 28Leukemia, Myelomonocytic, Acute 26Leukemia, Monocytic, Acute 26Myelodysplastic Syndromes 24Leukemia, Erythroblastic, Acute 23Leukemia, Megakaryoblastic, Acute 22Congenital Abnormalities 21Leukemia, Promyelocytic, Acute 13Leukemia, Myelomonocytic, Chronic 12Anemia, Refractory, with Excess of Blasts 12Recurrence 8Myeloproliferative Disorders 8Leukemia, Myelogenous, Chronic, BCR-ABL Positive 8Lymphoma 7Leukemia, Myeloid, Chronic-Phase 7Leukemia, Eosinophilic, Acute 7Leukemia, Biphenotypic, Acute 7Leukemia, Basophilic, Acute 6Carcinoma, Hepatocellular 6Blast Crisis 6Neoplasm, Residual 4Multiple Myeloma 4Lymphoma, Non-Hodgkin 4Lymphoma, Large B-Cell, Diffuse 4Lymphoma, Follicular 4Neutropenia 3Neoplasms, Plasma Cell 3Lymphoma, Large-Cell, Immunoblastic 3

Interventions

Sorafenib 61Bevacizumab 42Oxaliplatin 24Doxorubicin 22Radiosurgery 20Gemcitabine 20Fluorouracil 20Nivolumab 19durvalumab 18Radiofrequency Ablation 18pembrolizumab 17Capecitabine 17lenvatinib 16Cisplatin 16atezolizumab 13Leucovorin 13Radiotherapy 11tremelimumab 10Cyclophosphamide 10Carboplatin 10Irinotecan 9Ipilimumab 9Drug Therapy 9Everolimus 8Cryosurgery 8toripalimab 7fludarabine 7Sunitinib 7Chemotherapy, Adjuvant 7Melphalan 6

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Interventional × Liver Neoplasms × Idarubicin × Clear all
NCT02185768 2025-07-04

IDASPHERE II

Federation Francophone de Cancerologie Digestive

Phase 2 Completed
46 enrolled 11 charts
Gastrointestinal

Liver Neoplasms

NCT06492408 2024-07-09

Neoadjuvant Intra-tumor Double Immunotherapy for Hepatocellular Carcinoma.

Second Affiliated Hospital of Guangzhou Medical University

Phase 2 Recruiting
90 enrolled
Gastrointestinal

Carcinoma, Hepatocellular, Liver Neoplasms

NCT06482801 2024-07-01

Checkpoint Inhibitor Combinations Therapy as First Line for HCC Via IT

Second Affiliated Hospital of Guangzhou Medical University

Phase 2 Recruiting
90 enrolled
Gastrointestinal

Carcinoma, Hepatocellular, Liver Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡